Get started

Eli Lilly and Company

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

LLY chart

Key stats

Market capitalization
509.895BUSD
Dividends yield (FY)
0.84%
Price to earnings Ratio (TTM)
76.82
Basic EPS (TTM)
7.10USD
Net income
6.245BUSD
Revenue
28.541BUSD
Shares float
847.7M
Beta
0.21

About Eli Lilly and Company

Sector
Health Technology
CEO
David A. Ricks
Headquarters
Indianapolis
Website
lilly.com
Employees (FY)
39K
Founded
1876
ISIN
US5324571083

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Ideas

ELI LILLY: Possible to start a strong multi week correction.Eli Lilly has seen enormous growth over the past few years and in particularly in 2023. This Channel Up on the log chart's 1W timeframe is the best depiction of the long term trend. The 1W outlook got extremely overbought technically three weeks ago (RSI = 68.989, MACD = 46.590, ADX = 60.019) and is
4
LLY, This ALL-TIME-HIGH ROCKET is a NEVER ENDING STORY!Hello There! Welcome to my new analysis about LLY on several timeframe perspectives. LLY printed an major bullish breakout literally over night bouncing out of the range. In the recent times the pharma industry transformed into a eager bullish environment since the gains seen because of the "pande
4
ELI LILLY Hit the top of the 4-year Channel. Relief sell-off?Earlier this year we gave a strong buy signal on Eli Lilly and Company (LLY) on March 01 (see chart below) where we called for the most optimal buy entry exactly at the bottom of the bullish pattern: The price has now hit (last week) the top of the 4 year logarithmic Channel Up, highly overboug
$LLY, Price correction?Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Positive: Yields high return on invested capital Has raised its dividend for 8 consecutive years 13 analysts have revised their earnings upwards for the upcoming period Prominent player in the Pharmaceutic
1
LLY Eli Lilly: $555 | a look into an Outperformerfundamentally sound as it addresses world problems in the field of science medicine it acquires great companies to grow its portfolio and price wise lets investors get out at premium yet provides ample time to those who are patient to accumulate during down years impressive board leadership is to
LLY: The NVDA of Pharmaceuticals Showing Signs of Future DeclineIf we close the day as we are now, we will have confirmed a 3 Line Strike, a Bearish PPO Arrow, and a break below the 5 EMA on the Daily Timeframe just above the 3.618 Fibonacci Extension. From there I would expect LLY to first Fill the gap at $451.50 and beyond that I think it will revisit the 200-
More Absurdity1) Ridiculously overvalued. 2) Coiled stochastics monthly. 3) Overbought on all timeframes. 4) Heavy institutional ownership. 5) Log chart shows channel. Linear chart shows extreme price deviation. It can always go higher, as human stupidity is boundless, so just saying.
1
Eli Lily Local Top, Continuation Will ReturnEli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the
Long

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
No revenue here
This company hasn't generated any revenue in the last financial year
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.3Good
Learn more

See all brokers 

Sparks

Curated watchlists where LLY is featured.

See all sparks